Virus and immune drug join forces against deadly brain tumor
NCT ID NCT07472790
First seen Mar 20, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This early-stage study tests a new treatment for people with recurrent high-grade glioma, an aggressive brain cancer. The therapy combines a specially designed virus that targets cancer cells with an immunotherapy drug that helps the immune system attack the tumor. The main goal is to see if this combination can help patients live longer, and to check for safety. Only 15 adults whose cancer has returned after standard treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.